Cell Therapy Industry: Billion Dollar Global Business with Unlimited Potential

From production to patient: challenges and approaches for delivering cell therapies

“…The term "cell therapy" encompasses a range of activities including; therapies that look to either permanently or transiently replace cells, are immunomodulatory or use the cells as delivery vehicles for other technologies such as gene therapy (Mason et al, 2011). At its heart is the use of either the patient's own cells (autologous therapies) or donor cells (allogeneic therapies).…”

“…At its heart is the use of either the patient's own cells (autologous therapies) or donor cells (allogeneic therapies). Said to be the fourth therapeutic pillar of healthcare (Mason et al, 2011) and with induced pluripotent stem cells touted to be "a game changer" (Inoue et al, 2014), the cell therapy industry continues to grow and is estimated to reach an annual turnover of $20bn worldwide by 2025 (Cell Therapy Catapult website). Recent years have seen clinical trials show signs of success (Ratcliffe et al, 2013a) and products such as Prochymal (Osiris Therapeutics Inc) and ChondroCelect (TiGenix) gain regulatory approval.…”

Physicians’ Preference towards Stem Cells as Regenerative Medicine-Lacks Clarity

“…Scientists have been claiming cell therapy to be a different platform technology which may be a disruptive technology but still, cell therapy has progressed considerably which developed it to be a fourth and final therapeutic pillar for healthcare in accordance with pharmaceuticals, bio-pharmaceuticals and medical devices [40].…”

Cryopreservation and Cell Banking for Autologous Mesenchymal Stem Cell-Based Therapies

“…1 While there are a few cell-based products, which are commercially available, there are many more potential therapies in clinical development. 2,3 The two major types of stem cell-based products are those of allogeneic origin and of autologous origin.…”